COMPARISON
Oxytocin vs Triptorelin
3 attributes held for at least one of the two. 3 differ. Each value carries the register it came from and the date that register was read.
Answer
Oxytocin is authorised or registered in 9 and Triptorelin in 10 of the 10 registers read. Oxytocin: highest phase Phase 4 (after approval). Triptorelin: highest phase Phase 4 (after approval). 0 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Oxytocin | Triptorelin | |
|---|---|---|
| Registered trials differs | 952 clinicaltrials.gov · 2026-10-03 | 317 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA label, application not recorded: GUNA-GERIATRICS openfda · 2026-10-03T17:23:44.062Z | FDA-approved: Trelstar openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation differs | Nothing on record ema read 2026-08-31 | Authorised ema · 2026-08-31 |
LEGAL STATUS
Approval in each country read
| Country | Oxytocin | Triptorelin | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Not on the register | Authorised | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Registered | Registered | Regulator TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Authorised | Authorised | Regulator ALIMS |
| Singapore | Registered | Registered | Regulator HSA |
| Turkey | Ruhsatli | Ruhsatli | Regulator TITCK |
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.